On Wednesday, Shares of AT&T Inc. (NYSE:T), gained 1.53% to $32.56.
As part of AT&T’s ongoing efforts to drive economic development and investment in Kentucky, AT&T and representatives from the Green River Regional Industrial Development Authority and the Ohio County Economic Development Association recently declared that the Bluegrass Crossings Business Centre in Beaver Dam, Kentucky has been designated AT&T Fiber Ready.
The AT&T Fiber Ready designation assists economic development leaders more effectively position their communities for site selection by emphasizing the availability of high-speed, fiber-based services.
In today’s world, connectivity is vital to new employers and businesses of every type.
AT&T has been deploying high-speed, fiber-optic infrastructure across the Commonwealth for years, and the AT&T Fiber Ready designation is a tool for economic development leaders to highlight the assets available in their facilities.
AT&T Inc. is a holding company. The Company provides telecommunications services. Its services and products comprise wireless communications, data/broadband and Internet services, video services, local exchange services, long-distance services, telecommunications equipment, managed networking and wholesale services.
Shares of Nokia Corporation (ADR) (NYSE:NOK), inclined 3.19% to $6.79, during its last trading session.
Nokia Corporation declared that Nokia’s Board of Directors has resolved on a directed issuance of a maximum amount of 141 581 Nokia shares (NOKIA) held by the company to Nokia employees participating in the Employee Share Purchase Plan 2014. The one-year cycle of the Employee Share Purchase Plan 2014 ended on July 31, 2015.
Under the terms and conditions of the Employee Share Purchase Plan 2014 Nokia will offer one matching share for every two shares purchased under the plan which the participant still held as at July 31, 2015. The shares are issued without consideration. As the issued shares are held by the company, the total number of the company’s outstanding shares does not change as a consequence of the share issuance. The shares will be delivered to the employees in October 2015.
The Board of Directors approved the launch of the Employee Share Purchase Plan 2014 as part of the Nokia Equity Program 2014 on February 14, 2014 to encourage employee share ownership, commitment and engagement. The resolution to issue shares is based on the authorization granted to the Board by the Annual General Meeting on May 5, 2015.
Nokia Corporation (Nokia) invests in technologies. The Company operates through three business segments: Nokia Netoperates, HERE and Nokia Technologies. Nokia Netoperates offers network infrastructure software, hardware and services. Nokia Netoperates has two segments: Mobile Broadband and Global Services.
Shares of Infosys Ltd ADR (NYSE:INFY), inclined 5.71% to $19.08, during its last trading session.
Infosys Limited declared that it will create new Internet of Things (IoT) solutions, which will assist derive practical benefits from massive amounts of data generated through connected devices in the industrial enterprise.
Infosys has collaborated with GE, a digital industrial company, and others to develop these solutions, designed to assist manufacturers and other industrial enterprises improve asset efficiency and build more intelligent linkages between design, production and field testing.
The Industrial Internet Consortium (IIC), an international body of industries, governments and academics focused on developing best practices for the Industrial Internet, recently approved two Infosys-led testbeds:
- Asset Efficiency Testbed: This enables holistic monitoring, analysis and optimization of critical infrastructure assets. The first use case focuses on predictive maintenance for an industrial asset such as aircraft landing gear. A demonstration will be showcased at the GE’s Minds & Machines conference recently. The Asset Efficiency Testbed team comprised Infosys, GE and other industry partners.
- Industrial Digital Thread Testbed: This creates more intelligent linkages between the three phases of manufacturing - design, production and field testing/service. By capturing, analyzing and relaying real-time sensory and historical data at each of these phases, the Industrial Digital Thread (IDT) will generate insights that can assist field engineers and service teams identify the root cause of component failure easily, and provide faster corrections to flaws in design engineering and manufacturing operations. IDT leverages two open-standard big data analytics engines - the Infosys Information Platform (IIP), which provides in-memory data analytics and big data administration, and GE’s Predix platform that delivers data acquisition, processing and user interface and application development. IDT has been co-developed by Infosys and GE, and will be implemented first as a pilot project at GE Aviation.
Infosys Limited is engaged in consulting, technology, outsourcing and next-generation services. The Company’s solutions comprise application development and maintenance, independent validation services, infrastructure administration, engineering services comprising product engineering and life cycle solutions and business process administration; Administration Consulting, enterprise solutions and package implementation, systems integration and business intelligence; Products, business platforms and solutions, and technologies, such as cloud computing, enterprise mobility, digital, big data and analytics.
Finally, Exelixis, Inc. (NASDAQ:EXEL), ended its last trade with 0.36% gain, and closed at $5.61.
Exelixis declared that the European Medicines Agency’s Committee for Medical Products for Human Use (CHMP) has adopted a positive opinion of the Marketing Authorization Application for cobimetinib, a selective MEK inhibitor discovered by Exelixis, in combination with vemurafenib for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. The CHMP’s positive opinion will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. The European Commission is predictable to release its final decision regarding the approval of the combination of cobimetinib and vemurafenib by the end of 2015.
The CHMP’s recommendation is based on data from coBRIM, the international, randomized double-blind controlled phase 3 pivotal trial evaluating cobimetinib in combination with vemurafenib in formerly untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation.
The combination of cobimetinib and vemurafenib recently received its first approval in Switzerland, where cobimetinib is marketed as Cotellic™.
The coBRIM trial was conducted by Roche and Genentech, a member of the Roche Group. Genentech filed a New Drug Application (NDA) for cobimetinib in the United States, for which the Prescription Drug User Fee Act action date is November 11, 2015.
Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
